ANI Pharmaceuticals, Inc.
Balance Sheet
| Line Item | FY2025 | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 | FY2019 | FY2018 |
|---|---|---|---|---|---|---|---|---|
| Assets | ||||||||
| Cash & Equivalents | $285.6M | $144.9M | $221.1M | $48.2M | $100.3M | $7.9M | $62.3M | $43.0M |
| Accounts Receivable | $281.1M | $221.7M | $162.1M | $165.4M | $128.5M | $95.8M | $72.1M | $64.8M |
| Inventory | $143.1M | $136.8M | $111.2M | $105.4M | $81.7M | $60.8M | $48.2M | $40.5M |
| Total Current Assets | $753.1M | $528.5M | $519.8M | $344.3M | $321.8M | $170.3M | $187.7M | $152.9M |
| Property, Plant & Equipment | $62.5M | $56.9M | $44.6M | $43.2M | $52.7M | $41.3M | $40.6M | $38.1M |
| Goodwill | $62.5M | $60.0M | $28.2M | $28.2M | $27.9M | $3.6M | $3.6M | $3.6M |
| Intangible Assets (Excl. Goodwill) | $479.5M | $541.8M | $209.0M | $251.6M | $294.1M | $188.5M | $180.4M | $201.6M |
| Total Assets | $1.44B | $1.28B | $904.4M | $760.1M | $771.6M | $461.2M | $456.8M | $430.6M |
| Liabilities | ||||||||
| Accounts Payable | $62.6M | $45.7M | $36.7M | $29.3M | $23.0M | $11.3M | $14.6M | $8.9M |
| Total Current Liabilities | $278.1M | $194.5M | $145.5M | $99.4M | $87.5M | $78.6M | $61.7M | $165.5M |
| Long-Term Debt | $291.8M | $309.1M | $284.8M | $285.7M | $286.5M | $172.4M | $175.8M | $67.3M |
| Total Liabilities | $899.7M | $855.9M | $446.8M | $421.5M | $412.9M | $265.5M | $244.0M | $233.3M |
| Stockholders' Equity | ||||||||
| Retained Earnings | $-23.1M | $-100.3M | $-80.1M | $-97.3M | $-47.8M | $-5.0M | $17.6M | $11.5M |
| Total Stockholders' Equity | $540.7M | $403.7M | $432.7M | $313.7M | $333.9M | $195.7M | $212.8M | $197.3M |